X4 Pharmaceuticals (XFOR) Gross Margin (2024 - 2026)

X4 Pharmaceuticals (XFOR) has reported Gross Margin for 3 consecutive years, with 81.64% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Margin fell 184.0% year-over-year to 81.64%; the trailing twelve-month figure through Jun 2026 stood at 81.51% (down 149.0% YoY), and the FY2025 full-year result was 83.6%, up 1477.0% from the prior year.
• Gross Margin climbed to 81.64% in Q2 2026 per XFOR's latest filing, from 77.92% in the prior quarter.
• Across five years, Gross Margin topped out at 85.83% in Q4 2025 and bottomed at 52.4% in Q2 2024.
• Historically, Gross Margin has averaged 75.93% across 3 years, with a median of 80.11% in 2025.
• The sharpest annual moves came in 2025 and 2026: Gross Margin surged 3108 bps in 2025, then plunged 571 bps in 2026.
• Over 3 years, Gross Margin stood at 78.94% in 2024, then increased by 9 bps to 85.83% in 2025, then fell by 5 bps to 81.64% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 81.64%, 77.92%, and 85.83% for Q2 2026, Q1 2026, and Q4 2025 respectively.